Prognostic value of KRAS mutations in stage III colon cancer: post-hoc analysis of the PETACC8 phase III trial dataset

摘要: ABSTRACT Background The prognostic value of KRAS mutations in colon adenocarcinoma is controversial. We examined this question as an ancillary study the PETACC8 phase III trial. Patients and methods analyzed pronostic impact exon 2 stage cancer patients (n = 1657) receiving adjuvant FOLFOX ± cetuximab therapy included with BRAF-mutated cancers were excluded and, no difference was found for time to recurrence (TTR) disease-free survival (DFS) between treatment arms, both pooled analysis. Associations TTR DFS using a Cox proportional hazards model. Results 638 1657 tumors linked shorter (P Conclusion are independent predictors resected distal therapy. Future clinical trials setting should consider tumor location important stratification factors. Clinical trial number This trial: EUDRACT 2005-003463-23.